Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 3, Publication Date: Sep. 8, 2014, Page: 40-44
 skin metastases in 2 cohorts of non-scalp cooled and scalp cooled breast cancer patients which contributes to the discussion as to whether reservations concerning scalp cooling in the adjuvant chemotherapy setting are justified. Two retrospective observational studies are described. Non scalp cooled patients comprised 885 very thoroughly evaluated high-risk (≥4 positive lymph nodes) M0 breast cancer patients. Scalp cooled M0 patients (n=303) were collected in a registry of patients undergoing scalp cooling. Information on (scalp) skin metastases was obtained from patient files. After a median follow-up of 110 months, 25 of the non-scalp cooled patients (3%) developed skin metastases of whom four (0.5%) were located on the scalp. Scalp skin metastases always occurred synchronal with metastases elsewhere or in a later stage. After a median follow-up of 26 months, six scalp cooled patients (2%) developed skin metastases, none of which were on the scalp skin. Metastases in the scalp skin occurred with a very low frequency, even in high risk patients, and were never the first manifestation of advanced disease. Therefore the potential risk of scalp cooling during adjuvant chemotherapy is likely to be very low.&picture=http://www.aascit.org/aascit/decorators/img/journal/908.jpg)
| [1] | Corina van den Hurk, Research Department, Comprehensive Cancer Centre The Netherlands, PO Box 231, 5600 AE Eindhoven, The Netherlands. |
| [2] | Mariska van de Sande, Department of Clinical Oncology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands. |
| [3] | Wim Breed, Research Department, Comprehensive Cancer Centre The Netherlands, PO Box 231, 5600 AE Eindhoven, The Netherlands. |
| [4] | Johan Nortier, Department of Clinical Oncology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands. |
We assessed the incidence of (scalp) skin metastases in 2 cohorts of non-scalp cooled and scalp cooled breast cancer patients which contributes to the discussion as to whether reservations concerning scalp cooling in the adjuvant chemotherapy setting are justified. Two retrospective observational studies are described. Non scalp cooled patients comprised 885 very thoroughly evaluated high-risk (≥4 positive lymph nodes) M0 breast cancer patients. Scalp cooled M0 patients (n=303) were collected in a registry of patients undergoing scalp cooling. Information on (scalp) skin metastases was obtained from patient files. After a median follow-up of 110 months, 25 of the non-scalp cooled patients (3%) developed skin metastases of whom four (0.5%) were located on the scalp. Scalp skin metastases always occurred synchronal with metastases elsewhere or in a later stage. After a median follow-up of 26 months, six scalp cooled patients (2%) developed skin metastases, none of which were on the scalp skin. Metastases in the scalp skin occurred with a very low frequency, even in high risk patients, and were never the first manifestation of advanced disease. Therefore the potential risk of scalp cooling during adjuvant chemotherapy is likely to be very low.
Keywords
Scalp Cooling, Safety, Scalp Skin Metastases, Chemotherapy, Adjuvant Treatment Setting, Breast Cancer
Reference
| [01] | Mulders M, Vingerhoets A, Breed W: The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs 2008, 12(2):97-102. |
| [02] | Hurk van den CJ, Mols F, Vingerhoets AJ, Breed WP: Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-oncology 2010, 19(7):701-709. |
| [03] | Hurk van den CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP: Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta oncologica 2012, 51(4):497-504. |
| [04] | Breed WPM, Hurk van den CJG, Peerbooms M: Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. Expert Review Dermatology 2011, 6:109-125. |
| [05] | Hurk van den CJ, Breed WP, Nortier JW: Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 2012, 20(12):3255-3260. |
| [06] | Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. The New England journal of medicine 2003, 349(1):7-16. |
| [07] | Sande van de MA, Hurk van den CJ, Breed WP, Nortier JW: [Hoofdhuidkoeling toelaten bij adjuvante chemotherapie van borstkankerpatiënten; incidentie hoofdhuidmetastasen zeer gering] Ned Tijdschr Geneeskd [in Dutch] 2010, 154:A2134. |
| [08] | Hurk van den CJ, Eckel R, Poll van de-Franse LV, Coebergh JW, Nortier JW, Holzel D, Breed WP, Engel J: Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry. Breast cancer research and treatment 2011, 128(3):795-805. |
| [09] | Lemieux J, Amireault C, Provencher L, Maunsell E: Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast cancer research and treatment 2009, 118(3):547-552. |
| [10] | Spaeth D, Luporsi E, Weber B, Guiu S, Braun D, Rios M, Evon P, Ruck S: Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): A prospective study of 911 patients (pts). J Clin Oncol 2008, 26(may 20 suppl; abstr 9564). |
| [11] | Hurk van den CJ, van de Poll-Franse LV, Breed WP, Coebergh JW, Nortier JW: Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancer. Breast 2013, 22(5):1001-1004. |
| [12] | Lemieux J, Desbiens C, Hogue JC: Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up. Breast cancer research and treatment 2011, 128(2):563-566. |
| [13] | Janssen FE, Van Leeuwen GM, Van Steenhoven AA: Modelling of temperature and perfusion during scalp cooling. Phys Med Biol 2005, 50(17):4065-4073. |
| [14] | Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Muller A, von Moos R, Hugli-Dayer AM, Schefer H, Bodenmann S et al: Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 2013. |
